• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠常染色体显性多囊肾病中单核细胞趋化蛋白-1和骨桥蛋白在肾脏中的表达增加。

Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats.

作者信息

Cowley B D, Ricardo S D, Nagao S, Diamond J R

机构信息

Division of Nephrology & Hypertension, Department of Medicine, Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA.

出版信息

Kidney Int. 2001 Dec;60(6):2087-96. doi: 10.1046/j.1523-1755.2001.00065.x.

DOI:10.1046/j.1523-1755.2001.00065.x
PMID:11737583
Abstract

BACKGROUND

Human autosomal-dominant polycystic kidney disease (ADPKD) is variable in the rate of deterioration of renal function, with end-stage renal disease (ESRD) occurring in only approximately 50% of affected individuals. Evidence suggests that interstitial inflammation may be important in the development of ESRD in ADPKD. Han:SPRD rats manifest ADPKD that resembles the human disease. Homozygous cystic (Cy/Cy) rats develop rapidly progressive PKD and die near age 3 weeks. Heterozygous (Cy/+) females develop slowly progressive PKD without evidence of renal dysfunction until the second year of life, whereas heterozygous (Cy/+) males develop more aggressive PKD with renal failure beginning by 8 to 12 weeks of age.

METHODS

To examine the relationship between proinflammatory chemoattractants and the development of interstitial inflammation and ultimately renal failure in ADPKD, we evaluated monocyte chemoattractant protein-1 (MCP-1) and osteopontin mRNAs and proteins in kidneys from Han:SRPD rats.

RESULTS

MCP-1 and osteopontin mRNAs, expressed at low levels in kidneys from normal (+/+) animals at all ages, were markedly elevated in kidneys from 3-week-old Cy/Cy animals. In kidneys from heterozygous (Cy/+) adults of either gender, MCP-1 and osteopontin mRNAs were more abundant than normal; MCP-1 mRNA was more abundant in Cy/+ males than in females. Thus, chemoattractant mRNA expression correlated with the development of renal failure in Cy/Cy and Cy/+ rats. Osteopontin mRNA, localized by in situ hybridization, was moderately expressed in the renal medulla of normal animals; however, this mRNA was expressed at very high levels in the cystic epithelia of Cy/+ and Cy/Cy animals. MCP-1 and osteopontin proteins, localized by immunohistochemistry, were weakly detected in +/+ kidneys but were densely expressed in Cy/Cy and in adult Cy/+ kidneys, primarily over cystic epithelium. Increased expression of chemoattractants was associated with the accumulation of ED-1 positive cells (macrophages) in the interstitium of cystic kidneys.

CONCLUSIONS

We suggest that proinflammatory chemoattractants have a role in the development of interstitial inflammation and renal failure in ADPKD.

摘要

背景

人类常染色体显性遗传性多囊肾病(ADPKD)的肾功能恶化速率存在差异,只有约50%的受累个体发展至终末期肾病(ESRD)。有证据表明,间质炎症在ADPKD患者ESRD的发生过程中可能起重要作用。Han:SPRD大鼠表现出与人类疾病相似的ADPKD。纯合子囊性(Cy/Cy)大鼠发生快速进展性PKD,在3周龄左右死亡。杂合子(Cy/+)雌性大鼠发生缓慢进展性PKD,在生命的第二年之前无肾功能障碍的迹象,而杂合子(Cy/+)雄性大鼠发生更具侵袭性的PKD,8至12周龄时开始出现肾衰竭。

方法

为了研究促炎趋化因子与ADPKD中间质炎症的发展以及最终肾衰竭之间的关系,我们评估了Han:SRPD大鼠肾脏中的单核细胞趋化蛋白-1(MCP-1)和骨桥蛋白的mRNA及蛋白水平。

结果

MCP-1和骨桥蛋白的mRNA在各年龄段正常(+/+)动物的肾脏中表达水平较低,而在3周龄的Cy/Cy动物的肾脏中显著升高。在杂合子(Cy/+)成年雌雄大鼠的肾脏中,MCP-1和骨桥蛋白的mRNA比正常情况更为丰富;MCP-1 mRNA在Cy/+雄性大鼠中的表达比雌性大鼠更为丰富。因此,趋化因子mRNA的表达与Cy/Cy和Cy/+大鼠肾衰竭的发展相关。通过原位杂交定位,骨桥蛋白mRNA在正常动物的肾髓质中适度表达;然而,该mRNA在Cy/+和Cy/Cy动物的囊性上皮中高表达。通过免疫组织化学定位,MCP-1和骨桥蛋白在+/+肾脏中弱表达,但在Cy/Cy和成年Cy/+肾脏中高表达,主要在囊性上皮上。趋化因子表达的增加与囊性肾脏间质中ED-1阳性细胞(巨噬细胞)的积聚相关。

结论

我们认为促炎趋化因子在ADPKD间质炎症和肾衰竭的发展中起作用。

相似文献

1
Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats.大鼠常染色体显性多囊肾病中单核细胞趋化蛋白-1和骨桥蛋白在肾脏中的表达增加。
Kidney Int. 2001 Dec;60(6):2087-96. doi: 10.1046/j.1523-1755.2001.00065.x.
2
Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.常染色体显性多囊肾病模型Han:SPRD cy/+大鼠中ATP敏感性P2受体亚型表达的改变
Cells Tissues Organs. 2004;178(3):168-79. doi: 10.1159/000082247.
3
[Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].[改良低蛋白低脂饮食对多囊肾病实验模型肾脏组织学变化及代谢的影响]
Srp Arh Celok Lek. 2002 Jul-Aug;130(7-8):251-7.
4
CTGF Is Expressed During Cystic Remodeling in the PKD/Mhm (cy/+) Rat Model for Autosomal-Dominant Polycystic Kidney Disease (ADPKD).在常染色体显性多囊肾病(ADPKD)的PKD/Mhm(cy/+)大鼠模型的囊肿重塑过程中,结缔组织生长因子(CTGF)表达。
J Histochem Cytochem. 2017 Dec;65(12):743-755. doi: 10.1369/0022155417735513. Epub 2017 Oct 23.
5
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).用西罗莫司抑制哺乳动物雷帕霉素靶蛋白(mTOR)可减缓常染色体显性遗传性多囊肾病(ADPKD)的Han:SPRD大鼠的疾病进展。
Nephrol Dial Transplant. 2006 Mar;21(3):598-604. doi: 10.1093/ndt/gfi181. Epub 2005 Oct 12.
6
Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats.性别及性腺激素对大鼠遗传性多囊肾病进展的影响
Am J Kidney Dis. 1997 Feb;29(2):265-72. doi: 10.1016/s0272-6386(97)90039-1.
7
Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease.半胱天冬酶、Bcl-2蛋白与常染色体显性多囊肾病中的细胞凋亡
Kidney Int. 2002 Apr;61(4):1220-30. doi: 10.1046/j.1523-1755.2002.00250.x.
8
Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation.白藜芦醇通过抑制核因子 κB 诱导的炎症反应延缓多囊肾病的进展。
Nephrol Dial Transplant. 2016 Nov;31(11):1826-1834. doi: 10.1093/ndt/gfw058. Epub 2016 Apr 19.
9
Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.苯达喹治疗抑制MCP-1对多囊肾病大鼠模型的影响。
Nephron. 2015;129(1):52-61. doi: 10.1159/000369149. Epub 2014 Dec 17.
10
Autosomal-dominant polycystic kidney disease in the rat.大鼠常染色体显性遗传性多囊肾病
Kidney Int. 1993 Mar;43(3):522-34. doi: 10.1038/ki.1993.79.

引用本文的文献

1
Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era.托伐普坦时代常染色体显性多囊肾病的炎症生物标志物
Int J Mol Sci. 2025 Jan 28;26(3):1121. doi: 10.3390/ijms26031121.
2
Physiologic mechanisms underlying polycystic kidney disease.多囊肾病的生理机制。
Physiol Rev. 2025 Jul 1;105(3):1553-1607. doi: 10.1152/physrev.00018.2024. Epub 2025 Feb 12.
3
The impact of maternal obesity on polycystic kidney disease progression in a mouse model.母体肥胖对小鼠模型中多囊肾病进展的影响。
Am J Physiol Renal Physiol. 2025 Mar 1;328(3):F316-F327. doi: 10.1152/ajprenal.00227.2024. Epub 2025 Feb 5.
4
Multiomics profiling of mouse polycystic kidney disease progression at a single-cell resolution.单细胞分辨率下的小鼠多囊肾病进展的多组学分析。
Proc Natl Acad Sci U S A. 2024 Oct 22;121(43):e2410830121. doi: 10.1073/pnas.2410830121. Epub 2024 Oct 15.
5
Osteopontin deletion attenuates cyst growth but exacerbates fibrosis in mice with cystic kidney disease.骨桥蛋白缺失可减轻囊性肾病小鼠的囊肿生长,但可加重纤维化。
Physiol Rep. 2024 Sep;12(17):e70038. doi: 10.14814/phy2.70038.
6
Multi-omics profiling of mouse polycystic kidney disease progression at a single cell resolution.以单细胞分辨率对小鼠多囊肾病进展进行多组学分析。
bioRxiv. 2024 May 31:2024.05.27.595830. doi: 10.1101/2024.05.27.595830.
7
Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.用尿酸酶抑制剂升高血清尿酸会使大鼠和小鼠模型中的多囊肾病恶化。
Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F1004-F1015. doi: 10.1152/ajprenal.00372.2023. Epub 2024 Apr 18.
8
The Rat: A Preclinical Model of Polycystic Kidney Disease.大鼠:多囊肾病的临床前模型
Biomedicines. 2024 Feb 3;12(2):362. doi: 10.3390/biomedicines12020362.
9
cGAS Activation Accelerates the Progression of Autosomal Dominant Polycystic Kidney Disease.cGAS 激活加速常染色体显性多囊肾病的进展。
J Am Soc Nephrol. 2024 Apr 1;35(4):466-482. doi: 10.1681/ASN.0000000000000305. Epub 2024 Jan 22.
10
Cytokine Profiling of Cyst Fluid and Tumor-Associated Macrophages in Cystic Vestibular Schwannoma.囊性前庭神经鞘瘤囊液和肿瘤相关巨噬细胞的细胞因子分析。
Otol Neurotol. 2023 Dec 1;44(10):1073-1081. doi: 10.1097/MAO.0000000000004032. Epub 2023 Oct 19.